Moderna Sinks While Market Awaits Omicron Variant Updates
(Bloomberg) -- Moderna Inc. dropped more than 13% on Monday, making it the worst performing stock in the S&P 500 Index, a troubling turn for the vaccine maker that led the benchmark just last week.
It's the biggest drop in a month for Moderna, and it comes as investors weigh the risks of the omicron variant against a broader economic reopening. The U.S. Centers for Disease Control and Prevention signaled hope that existing vaccines could work on the virus variant, while the country's virus expert, Anthony Fauci, said in a CNN interview that the severity of illness may not be as bad as feared.
“It may decrease the need for annual boosting if the severity is no worse and we move somewhat closer to this elusive herd immunity,” Oppenheimer & Co. strategist Jared Holz said in an interview.
Moderna's much debated valuation is complicated by the market's inability to determine how long the pandemic will last and what the demand for vaccines will look like. Still, this selloff is surprising since much of the U.S. population is still in need of the original vaccine regimen or a booster -- and none of the recent updates indicate that vaccines sales will slow anytime soon, Holz said.
The leading vaccine makers, Pfizer Inc. and BioNTech SE, are expected to have new data about treating the variant potentially by the end of the week, and Moderna is expected to follow shortly after that, according to Asad Haider, a strategist with Goldman Sachs.
“The major question is whether boosting with existing vaccines will be effective in providing protection, particularly in the context of waning immunity,” Haider wrote in a note to clients. Until we have those results, stock sentiment may be tied to updates on transmission of the new variant, he added.
Other companies working on new shots also slumped. Vermont Senator Bernie Sanders further fanned the flames when he tweeted on Sunday that gains by Pfizer and Moderna stockholders are “obscene.” Pfizer fell 5.1%, the most in over a year, while BioNTech tumbled 19%. The Nasdaq Biotech Index, where Moderna comprises the third highest weighting, closed at the lowest since November 2020.
©2021 Bloomberg L.P.
-
Unhedged Position | Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
